A Phase I/Ib Study of the CDK Inhibitor Dinaciclib in CLL
John C. Byrd, MD, from OSUCCC – James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Clinical Pearls
John C. Byrd, MD, director of the division of hematology and a CLL specialist at the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
- Dinaciclib is a second-generation selective inhibitor of CDKs 1, 2, 5, and 9
- This agent was evaluated in a phase I/Ib expansion study in patients with relapsed or refractory CLL
- Unlike early CDK inhibitors, dinaciclib induced a high response rate (65-70%) and durable remissions
Recent Videos
Related Content
